CorMedix Inc.
CRMDHealthcare|Biotechnology|US
$5.32
+0.09 (+1.72%)
Tangible Book / Share
$0.92
Graham Number
$17.76
Cash / Share
$3.27
Clinical Trials (6)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06714864 Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age | Catheter-Related Infections | P4 | Recruiting | 36 | RCT, Open-label | (taurolidine and heparin) catheter lock solution, Standard of Care |
| NCT06822426 Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults And Adolescent Participants Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC) | Central Line Associated Blood Stream Infections (CLABSI) | P3 | Recruiting | 200 | RCT, Double-blind | (taurolidine and heparin) catheter lock solution, Heparin |
| NCT01391520 Efficacy and Safety of Deferiprone in Patients With Chronic Kidney Disease Undergoing a Cardiac Catheterization and Receiving Contrast Agent | Acute Kidney Injury | P3 | Withdrawn | — | RCT, Double-blind | deferiprone, Placebo |
| NCT02651428 Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection | Kidney Failure, Chronic, Catheter-Related Infections | P3 | Completed | 806 | RCT, Double-blind | Neutrolin, Heparin |
| NCT01146925 Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury | Contrast-Induced Acute Kidney Injury | P2 | Completed | 60 | RCT, Double-blind | CRMD-001-Deferiprone, Placebo |
| NCT06707480 Expanded Access Program for Patients at Risk for Catheter-related Infections Who Are Not Eligible for DefenCath® Clinical Trials | Catheter-related Bloodstream Infection | NO_LONGER_AVAILABLE | — | — | Taurolidine and Heparin |